Keita Masuzawa

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Shigenari Nukaga, Hiroyuki Yasuda, Katsuya Tsuchihara et al. · Cancer Research · 2017 · 173 citations

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations

Keita Masuzawa, Hiroyuki Yasuda, Junko Hamamoto et al. · Oncotarget · 2017 · 55 citations · Full text

Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare <i>EGFR</i> mutations

Shinnosuke Ikemura, Hiroyuki Yasuda, Shingo Matsumoto et al. · Proceedings of the National Academy of Sciences · 2019 · 53 citations · Full text

IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer

Tadashi Manabe, Hiroyuki Yasuda, Hideki Terai et al. · Molecular Cancer Research · 2020 · 52 citations · Full text

Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations

Hanako Hasegawa, Hiroyuki Yasuda, Junko Hamamoto et al. · Lung Cancer · 2018 · 50 citations

Insertion Mutations, Cetuximab Combination Therapy, Non-small-cell Lung Cancer +8